Megan B. Barnet
Darlinghurst, NSW, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Reply to Bousdar et al.: Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 05, 2025
Polymicrobial Emphysematous Hepatitis With Clindamycin-Resistant Clostridium Perfringens in a Patient With Pancreatic Cancer.
Journal: ACG case reports journal
Published: September 17, 2025
Common inherited loss-of-function mutations in the innate sensor NOD2 contribute to exceptional immune response to cancer immunotherapy.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: July 07, 2025
Thymoma-Induced Severe Biventricular Failure without Myasthenia Gravis: Investigating Tachycardia-Induced Cardiomyopathy.
Journal: The American journal of case reports
Published: March 12, 2025
Psychological impact of exceptional response in people with advanced cancer: a qualitative exploration.
Journal: Journal of cancer survivorship : research and practice
Published: May 11, 2024
Oligometastatic colorectal adenocarcinoma to the spleen and ovaries.
Journal: Journal of surgical case reports
Published: January 21, 2024
Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II.
Journal: Frontiers in endocrinology
Published: October 10, 2023
Blood and guts: peripheral immune correlates of immunotherapy-induced colitis.
Journal: Immunology and cell biology
Published: November 03, 2022
Editorial: Decoding checkpoint inhibitor-induced endocrinopathies.
Journal: Frontiers in endocrinology
Published: July 06, 2022
Insights Into the Host Contribution of Endocrine Associated Immune-Related Adverse Events to Immune Checkpoint Inhibition Therapy.
Journal: Frontiers in oncology
Published: March 11, 2022
Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 17, 2020
Last Updated: 09/26/2026